ReP USP - Resultado da busca

Artigo de periodico
A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer (2012)
Ferrarotto, Renata; Machado, Karime; Mak, Milena P.; Shah, Neeraj; Takahashi, Tiago K.; Costa, Frederico P.; Overman, Michael J.; Kopetz, Scott; Hoff, Paulo M.
Fonte: European Journal of Cancer. Unidade: FM
Assuntos: NEOPLASIAS COLORRETAIS, METÁSTASE NEOPLÁSICA, ADENOCARCINOMA, ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERRAROTTO, Renata et al. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. European Journal of Cancer, v. 48, n. 6, p. 820-826, 2012Tradução . . Disponível em: https://doi.org/10.1016/j.ejca.2012.01.008. Acesso em: 26 nov. 2025.
APA
Ferrarotto, R., Machado, K., Mak, M. P., Shah, N., Takahashi, T. K., Costa, F. P., et al. (2012). A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. European Journal of Cancer, 48( 6), 820-826. doi:10.1016/j.ejca.2012.01.008
NLM
Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer [Internet]. European Journal of Cancer. 2012 ; 48( 6): 820-826.[citado 2025 nov. 26 ] Available from: https://doi.org/10.1016/j.ejca.2012.01.008
Vancouver
Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer [Internet]. European Journal of Cancer. 2012 ; 48( 6): 820-826.[citado 2025 nov. 26 ] Available from: https://doi.org/10.1016/j.ejca.2012.01.008
Artigo de periodico
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury (2011)
Overman, Michael J; Maru, Dipen M; Charnsangavej, Chusilp; Loyer, Evelyn M; Wang, Huamin; Oathak, Priyanka; Eng, Cathy; Hoff, Paulo Marcelo Gehm; Vauthey, Jean-Nicolas; Wolff, Robert a; Kopetz, Scott
Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: BIOMARCADORES, FÍGADO (LESÕES;FISIOPATOLOGIA), HEPATOPATIAS (FISIOPATOLOGIA;ETIOLOGIA;COMPLICAÇÕES), MEDICAMENTO (EFEITOS ADVERSOS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OVERMAN, Michael J et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of clinical oncology, v. 28, n. 14, p. 2549-2555, 2011Tradução . . Disponível em: https://doi.org/10.1200/JCO.2009.27.5701. Acesso em: 26 nov. 2025.
APA
Overman, M. J., Maru, D. M., Charnsangavej, C., Loyer, E. M., Wang, H., Oathak, P., et al. (2011). Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of clinical oncology, 28( 14), 2549-2555. doi:10.1200/JCO.2009.27.5701
NLM
Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Oathak P, Eng C, Hoff PMG, Vauthey J-N, Wolff R a, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury [Internet]. Journal of clinical oncology. 2011 ; 28( 14): 2549-2555.[citado 2025 nov. 26 ] Available from: https://doi.org/10.1200/JCO.2009.27.5701
Vancouver
Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Oathak P, Eng C, Hoff PMG, Vauthey J-N, Wolff R a, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury [Internet]. Journal of clinical oncology. 2011 ; 28( 14): 2549-2555.[citado 2025 nov. 26 ] Available from: https://doi.org/10.1200/JCO.2009.27.5701
Artigo de periodico
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance (2010)
Kopetz, Scott; Hoff, Paulo M.; Morris, Jeffrey S.; Wolff, Robert A.; Eng, Cathy; Glover, Katrina Y.; Adinin, Rosie; Overman, Michael J.; Valero, Vincete; Wen, Sijin; Lieu, Christopher; Yan, Shaoyu; Tran, Hai T.; Ellis, Lee M.; Abbruzzese, James L.; Heymach, John V.
Fonte: Journal of Clinical Oncology. Unidade: FM
Assuntos: NEOPLASIAS COLORRETAIS, ANTINEOPLÁSICOS (USO TERAPÊUTICO), BIOMARCADORES, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOPETZ, Scott et al. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology, v. 28, n. 3, p. 453-459, 2010Tradução . . Disponível em: https://doi.org/10.1200/JCO.2009.24.8252. Acesso em: 26 nov. 2025.
APA
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., et al. (2010). Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology, 28( 3), 453-459. doi:10.1200/JCO.2009.24.8252
NLM
Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance [Internet]. Journal of Clinical Oncology. 2010 ; 28( 3): 453-459.[citado 2025 nov. 26 ] Available from: https://doi.org/10.1200/JCO.2009.24.8252
Vancouver
Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance [Internet]. Journal of Clinical Oncology. 2010 ; 28( 3): 453-459.[citado 2025 nov. 26 ] Available from: https://doi.org/10.1200/JCO.2009.24.8252

Unidades USP

ReP

Filtros

Autores

Assuntos